Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF

PHASE3CompletedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

October 31, 2013

Study Completion Date

January 31, 2014

Conditions
Pulmonary Fibrosis
Interventions
DRUG

N-acetylcysteine (NAC)

Participants will receive 600 mg of NAC three times a day.

DRUG

Placebo

Participants will receive placebo each day.

Trial Locations (26)

10021

Weill Medical College of Cornell University, New York

10029

Mount Sinai Hospital, New York

14620

Highland Hospital - University of Rochester Medical Center, Rochester

19104

University of Pennsylvania Health System, Philadelphia

19140

Temple University, Philadelphia

27705

Duke Universtiy, Durham

29425

Medical University of South Carolina, Charleston

33136

University of Miami Miller School of Medicine, Miami

35294

University of Alabama - Birmingham, Birmingham

37232

Vanderbilt University, Nashville

40425

University of Louisville, Louisville

44195

Cleveland Clinic, Cleveland

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic, Rochester

60637

University of Chicago, Chicago

63107

St. Luke's Hospital, Chesterfield

70118

Tulane University, New Orleans

75390

University of Texas Southwestern Medical Center, Dallas

80206

National Jewish Medical and Research Center, Denver

84108

University of Utah Health Research Center, Salt Lake City

90095

University of California - Los Angeles, Los Angeles

94110

University of California - San Francisco, San Francisco

98165

University of Washington, Seattle

06520

Yale University School of Medicine, New Haven

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Duke University

OTHER

NCT00650091 - Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF | Biotech Hunter | Biotech Hunter